Despite encouraging results with azacitidine in VEXAS patients [8], follow-up of the efficacy of azacitidine in 4 VEXAS patients with MDS compared to 22 MAI MDS patients has not yet shown a conclusive result, suggesting a challenge for the therapeutic management of patients with UBA1 mutations [34]. Here, UBA1 is linked to myelodysplastic syndrome.